Results of a study examining ibrutinib combined with bendamustine and rituximab for first line treatment of mantle cell lymphoma. (Abstract only)
Home / Resource Library / Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma